Received May 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
inadvertently administered a pediatric dose of ENGERIX-B by GSK (GlaxoSmithKline) to an adult patient.; Underdose; This non-serious case was reported by a other health professional via other manufacturer and described the occurrence of adult use of a child product in a adult patient who received HBV (Engerix B pediatric) for prophylaxis. On an unknown date, the patient received Engerix B pediatric. On an unknown date, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: inadvertently administered a pediatric dose of ENGERIX-B by GSK (GlaxoSmithKline) to an adult patient.) and underdose (Verbatim: Underdose). The outcome of the adult use of a child product and underdose were not applicable. Additional Information: GSK Receipt Date: 13-MAY-2025 Inadvertently administered a pediatric dose of Engerix-B to a patient, which led adult use of a child product and underdose.